
Carol M. Koslow
Examiner (ID: 12920, Phone: (571)272-1371 , Office: P/1734 )
| Most Active Art Unit | 1734 |
| Art Unit(s) | 1734, 1754, 1793, 1755, 1108 |
| Total Applications | 5011 |
| Issued Applications | 4022 |
| Pending Applications | 258 |
| Abandoned Applications | 784 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17843794
[patent_doc_number] => 11433137
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Compounds for treating cancer
[patent_app_type] => utility
[patent_app_number] => 16/714938
[patent_app_country] => US
[patent_app_date] => 2019-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 14
[patent_no_of_words] => 38984
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714938
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/714938 | Compounds for treating cancer | Dec 15, 2019 | Issued |
Array
(
[id] => 15993399
[patent_doc_number] => 20200172570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => ANTIMICROBIAL PEPTIDES AND COMPOSITIONS, METHODS, ARTICLES & KITS RELATING THERETO
[patent_app_type] => utility
[patent_app_number] => 16/696904
[patent_app_country] => US
[patent_app_date] => 2019-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17180
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16696904
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/696904 | Antimicrobial peptides and compositions, methods, articles and kits relating thereto | Nov 25, 2019 | Issued |
Array
(
[id] => 19731153
[patent_doc_number] => 12209144
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
[patent_app_type] => utility
[patent_app_number] => 17/296679
[patent_app_country] => US
[patent_app_date] => 2019-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42184
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296679
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/296679 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | Nov 25, 2019 | Issued |
Array
(
[id] => 17370292
[patent_doc_number] => 20220025344
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => LPL-GPIHBP1 FUSION POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/296369
[patent_app_country] => US
[patent_app_date] => 2019-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296369
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/296369 | LPL-GPIHBP1 FUSION POLYPEPTIDES | Nov 24, 2019 | Abandoned |
Array
(
[id] => 17480618
[patent_doc_number] => 20220088122
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => COMPOUND, USE, PHARMACEUTICAL COMPOSITION, METHOD OF DIAGNOSIS, METHOD OF TREATMENT, AND METHOD OF TRANSPORTATION AND/OR INTERNALIZATION OF A COMPOUND INTO EUKARYOTIC CELLS
[patent_app_type] => utility
[patent_app_number] => 17/309373
[patent_app_country] => US
[patent_app_date] => 2019-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7265
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309373
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/309373 | Compound, use, pharmaceutical composition, method of diagnosis, method of treatment, and method of transportation and/or internalization of a compound into eukaryotic cells | Nov 21, 2019 | Issued |
Array
(
[id] => 15931055
[patent_doc_number] => 20200157161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => COMPOSITIONS FROM GASTROINTESTINAL TRACT MUCINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/687665
[patent_app_country] => US
[patent_app_date] => 2019-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25614
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687665
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/687665 | COMPOSITIONS FROM GASTROINTESTINAL TRACT MUCINS AND USES THEREOF | Nov 17, 2019 | Abandoned |
Array
(
[id] => 17805869
[patent_doc_number] => 20220257704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => COMBINATION OF CHEMOTHERAPY WITH RECOMBINANT S. ROLFSII LECTIN
[patent_app_type] => utility
[patent_app_number] => 17/294570
[patent_app_country] => US
[patent_app_date] => 2019-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13978
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294570
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/294570 | COMBINATION OF CHEMOTHERAPY WITH RECOMBINANT S. ROLFSII LECTIN | Nov 17, 2019 | Pending |
Array
(
[id] => 15493219
[patent_doc_number] => 20200046798
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1
[patent_app_type] => utility
[patent_app_number] => 16/669151
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 140
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669151
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/669151 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Oct 29, 2019 | Abandoned |
Array
(
[id] => 15866193
[patent_doc_number] => 20200140500
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => HIGH THROUGHPUT METHODS, PROTEIN INHIBITORS, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/586479
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586479
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/586479 | HIGH THROUGHPUT METHODS, PROTEIN INHIBITORS, AND USES THEREOF | Sep 26, 2019 | Abandoned |
Array
(
[id] => 16710482
[patent_doc_number] => 20210077629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => IMPROVED PEPTIDE PHARMACEUTICALS
[patent_app_type] => utility
[patent_app_number] => 16/579799
[patent_app_country] => US
[patent_app_date] => 2019-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56444
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16579799
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/579799 | IMPROVED PEPTIDE PHARMACEUTICALS | Sep 22, 2019 | Abandoned |
Array
(
[id] => 16253540
[patent_doc_number] => 20200262914
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => PEPTIDES SELECTIVE FOR BCL-2 FAMILY PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/573881
[patent_app_country] => US
[patent_app_date] => 2019-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28613
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/573881 | Peptides selective for Bcl-2 family proteins | Sep 16, 2019 | Issued |
Array
(
[id] => 16178272
[patent_doc_number] => 20200225240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => USE OF CD36 TO IDENTIFY CANCER SUBJECTS FOR TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/549961
[patent_app_country] => US
[patent_app_date] => 2019-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11928
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16549961
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/549961 | USE OF CD36 TO IDENTIFY CANCER SUBJECTS FOR TREATMENT | Aug 22, 2019 | Abandoned |
Array
(
[id] => 15586471
[patent_doc_number] => 20200069770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-05
[patent_title] => TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS
[patent_app_type] => utility
[patent_app_number] => 16/542261
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49847
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542261
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/542261 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS | Aug 14, 2019 | Abandoned |
Array
(
[id] => 15493239
[patent_doc_number] => 20200046808
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => DILUTE SURFACTANT OR ISOLATED SURFACTANT PROTEIN SOLUTION FOR THE REDUCTION OF SURFACE TENSION IN THE LUNG
[patent_app_type] => utility
[patent_app_number] => 16/542169
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6004
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -63
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542169
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/542169 | DILUTE SURFACTANT OR ISOLATED SURFACTANT PROTEIN SOLUTION FOR THE REDUCTION OF SURFACE TENSION IN THE LUNG | Aug 14, 2019 | Abandoned |
Array
(
[id] => 16970481
[patent_doc_number] => 11066442
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-20
[patent_title] => Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
[patent_app_type] => utility
[patent_app_number] => 16/526862
[patent_app_country] => US
[patent_app_date] => 2019-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 20
[patent_no_of_words] => 22276
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16526862
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/526862 | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation | Jul 29, 2019 | Issued |
Array
(
[id] => 15828631
[patent_doc_number] => 20200129597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
[patent_app_type] => utility
[patent_app_number] => 16/519732
[patent_app_country] => US
[patent_app_date] => 2019-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519732
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/519732 | MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE | Jul 22, 2019 | Abandoned |
Array
(
[id] => 15035639
[patent_doc_number] => 20190328824
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => HYDROGEL COMPOSITION AND ASSOCIATED METHOD OF USE
[patent_app_type] => utility
[patent_app_number] => 16/510381
[patent_app_country] => US
[patent_app_date] => 2019-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19628
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510381
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/510381 | HYDROGEL COMPOSITION AND ASSOCIATED METHOD OF USE | Jul 11, 2019 | Abandoned |
Array
(
[id] => 19089746
[patent_doc_number] => 11951165
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-09
[patent_title] => Conjugated vaccine carrier proteins
[patent_app_type] => utility
[patent_app_number] => 16/459303
[patent_app_country] => US
[patent_app_date] => 2019-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 94230
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16459303
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/459303 | Conjugated vaccine carrier proteins | Jun 30, 2019 | Issued |
Array
(
[id] => 15020889
[patent_doc_number] => 20190321449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders
[patent_app_type] => utility
[patent_app_number] => 16/456717
[patent_app_country] => US
[patent_app_date] => 2019-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19500
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16456717
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/456717 | Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders | Jun 27, 2019 | Abandoned |
Array
(
[id] => 15320785
[patent_doc_number] => 20200000722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => SYNTHETIC POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/455800
[patent_app_country] => US
[patent_app_date] => 2019-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14091
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 360
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16455800
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/455800 | Synthetic polypeptides and uses thereof | Jun 27, 2019 | Issued |